{"product_id":"immune-checkpoint-inhibitors-in-oncology-markets","title":"Immune Checkpoint Inhibitors in Oncology Markets","description":"\u003cp\u003e\u003cstrong\u003eImmune Checkpoint Inhibitors in Oncology: Market Forecast, Competitive Landscape and Strategic Opportunities, 2027–2031\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGlobal forecasts by indication, target, product, molecule format and treatment setting, with country and regional breakouts and 25 company profiles.\u003c\/p\u003e\n\u003cdiv style=\"margin: 24px 0; padding: 20px 24px; border: 2px solid #1f3a5f; border-radius: 8px; text-align: center;\"\u003e\n\u003cp style=\"margin: 0 0 6px; font-size: 1.15em;\"\u003e\u003cstrong\u003eSee inside before you buy\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp style=\"margin: 0 0 16px;\"\u003eGet a free sample: the full table of contents plus real pages of analysis, company profiles, tables and charts.\u003c\/p\u003e\n\u003cp style=\"margin: 0;\"\u003e\u003ca href=\"\/pages\/request-a-sample?report=ONCCHECK\" style=\"display: inline-block; padding: 12px 28px; background: #1f3a5f; color: #ffffff; text-decoration: none; border-radius: 6px; font-weight: bold;\"\u003eRequest a free sample\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eOur Take\u003c\/h3\u003e\n\u003cp\u003eThe checkpoint inhibitor market is about to stop growing in its core. Keytruda and Opdivo begin losing exclusivity from 2028, and we forecast the market to peak at $75.7 billion in 2028 before biosimilars pull it down. The winners of the next five years will be the challengers with early-stage labels, not the incumbents, and PD-(L)1\/VEGF bispecifics remain an expensive, unproven bet rather than the next standard backbone.\u003c\/p\u003e\n\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0735\/8244\/4623\/files\/ONCCHECK_Key_Graphic.png?v=1792523663\" alt=\"The checkpoint patent cliff: Keytruda and Opdivo, biosimilars and challengers, 2026 to 2031\" style=\"width:100%;height:auto;\"\u003e\u003c\/p\u003e\n\u003ch3\u003eSituation Analysis: what is really happening\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eThe patent cliff arrives in 2029. \u003c\/strong\u003eKeytruda and Opdivo lose exclusivity from 2028 and the first Keytruda biosimilar filing was accepted in October 2026. We expect brand erosion to start earlier than the 2033 timing many analysts assume.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiosimilars become a major segment. \u003c\/strong\u003ePembrolizumab and nivolumab biosimilars go from nothing to one of the largest product segments by 2031, with Samsung Bioepis and Formycon\/Zydus first in line.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGrowth moves earlier and to the challengers. \u003c\/strong\u003ePerioperative and first-line use grow while later-line use shrinks. Imfinzi, Libtayo, Opdualag and China-originated PD-1s are the growth brands, and bladder cancer is the fastest-growing indication.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eThe bispecific money arrived before the proof. \u003c\/strong\u003ePD-(L)1\/VEGF licensing deals exceed $25 billion in headline value, but the HARMONi-3 interim miss leaves the class unproven globally. The November 14 FDA decision on ivonescimab is the next test.\u003c\/li\u003e\n\u003cli\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0735\/8244\/4623\/files\/Key_Findings_1026.png?v=1792450709\" alt=\"\"\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eCompany Analysis: who is positioned, who is exposed\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMerck \u0026amp; Co.: \u003c\/strong\u003eKeytruda carries about half of Merck's revenue into the patent cliff. Keytruda Qlex and the Padcev combination slow the loss but do not stop it.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBristol Myers Squibb: \u003c\/strong\u003eThe next most exposed, with Opdivo eroding. Opdualag, Opdivo Qvantig and the BioNTech bispecific pumitamig are its bridge.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAstraZeneca: \u003c\/strong\u003eImfinzi is the biggest brand winner, built on curative-intent indications and a later loss of exclusivity than its rivals.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSummit Therapeutics \/ Akeso: \u003c\/strong\u003eIvonescimab is the single most important test of the bispecific thesis; the FDA decision and global HARMONi-3 data decide its value.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRoche: \u003c\/strong\u003eTecentriq holds its niches, but the TIGIT failure left Roche without a next-generation checkpoint.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSamsung Bioepis: \u003c\/strong\u003eFirst with global Phase 3 data for a Keytruda biosimilar, positioning it as an early winner from the cliff, subject to litigation with Merck.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePlus 19 more company profiles covering big pharma, China-originated developers, biosimilar makers and technology licensors.\u003c\/p\u003e\n\u003ch3\u003eQuestions this report answers\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eWhen will Keytruda and Opdivo biosimilars launch, and how fast will brand sales fall?\u003c\/li\u003e\n\u003cli\u003eWhich checkpoint brands keep growing through the patent cliff?\u003c\/li\u003e\n\u003cli\u003eWill PD-1\/VEGF bispecifics replace PD-1 as the standard backbone?\u003c\/li\u003e\n\u003cli\u003eHow much revenue moves into perioperative and adjuvant use?\u003c\/li\u003e\n\u003cli\u003eHow are China-originated checkpoint inhibitors changing price and competition?\u003c\/li\u003e\n\u003cli\u003eHow will Medicare price negotiation affect Keytruda and Opdivo?\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eWhat’s inside\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e183 pages, 23 chapters\u003c\/li\u003e\n\u003cli\u003e25 company profiles with technology, pipeline, strategy and risks\u003c\/li\u003e\n\u003cli\u003eForecasts 2027–2031 from a 2026 base (actual) year, by indication, target, product, molecule format and treatment setting, for 14 countries and regions\u003c\/li\u003e\n\u003cli\u003eApproved product registry and 2025 sales benchmarks\u003c\/li\u003e\n\u003cli\u003ePatent cliff and biosimilar readiness, Medicare negotiation, and a China ecosystem chapter\u003c\/li\u003e\n\u003cli\u003eDelivered as 3 files: full report PDF, Situation Analysis PDF, and Excel workbook of all charts and tables\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0735\/8244\/4623\/files\/ONCCHECK_Table_of_Contents.pdf\" rel=\"noopener\" target=\"_blank\"\u003eDownload the Table of Contents (PDF)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv style=\"margin: 24px 0; padding: 20px 24px; border: 2px solid #1f3a5f; border-radius: 8px; text-align: center;\"\u003e\n\u003cp style=\"margin: 0 0 6px; font-size: 1.15em;\"\u003e\u003cstrong\u003eSee inside before you buy\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp style=\"margin: 0 0 16px;\"\u003eGet a free sample: the full table of contents plus real pages of analysis, company profiles, tables and charts.\u003c\/p\u003e\n\u003cp style=\"margin: 0;\"\u003e\u003ca href=\"\/pages\/request-a-sample?report=ONCCHECK\" style=\"display: inline-block; padding: 12px 28px; background: #1f3a5f; color: #ffffff; text-decoration: none; border-radius: 6px; font-weight: bold;\"\u003eRequest a free sample\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eWho buys this report\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBusiness development and licensing teams: \u003c\/strong\u003etrack the bispecific race and find in-licensing candidates.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInvestors and equity analysts: \u003c\/strong\u003emodel the patent cliff and judge who holds value.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiosimilar developers and manufacturers: \u003c\/strong\u003esize the opportunity and plan launch timing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOncology drug developers: \u003c\/strong\u003echoose a checkpoint backbone and combination partners.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eLicences and support\u003c\/h3\u003e\n\u003cp\u003eYour order is delivered to your inbox immediately. Every licence includes unlimited questions to the analyst and custom data breakouts, including any country not shown. Single User, Five User and Enterprise licences contain the same report; they differ only in how many people may use it.\u003c\/p\u003e\n\u003ch3\u003eAbout the author\u003c\/h3\u003e\n\u003cp\u003eGreg Powell, B.Sc., M.B.A., has worked in laboratory testing and management for more than 20 years, with executive training at Harvard Business School and the Burke Institute.\u003c\/p\u003e","brand":"OncoPharma Insights","offers":[{"title":"Single User","offer_id":67804857827407,"sku":null,"price":6995.0,"currency_code":"USD","in_stock":true},{"title":"Five User","offer_id":67804857860175,"sku":null,"price":9995.0,"currency_code":"USD","in_stock":true},{"title":"Enterprise License","offer_id":67804857892943,"sku":null,"price":13995.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0735\/8244\/4623\/files\/ONCCHECK1026Cover.png?v=1792449515","url":"https:\/\/oncopharmainsights.com\/products\/immune-checkpoint-inhibitors-in-oncology-markets","provider":"OncoPharma Insights","version":"1.0","type":"link"}